Emergent BioSolutions Announces Approximately $27 Million in Incremental Sales to Supply International Customers with Five Critical Medical Countermeasure Products
Emergent Biosolutions, Inc. (EBS)
Last emergent biosolutions, inc. earnings: 4/30 04:08 pm
Check Earnings Report
US:NYSE Investor Relations:
investors.emergentbiosolutions.com
Company Research
Source: GlobeNewswire
GAITHERSBURG, Md., March 18, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has recently secured approximately $27 million in international orders targeted for delivery in 2025 associated with its medical countermeasures (MCM) portfolio. These orders will help address potential threats of smallpox and anthrax and will contribute to the overall supply of MCM’s to the international market in 2025. “Emergent is a trusted partner to supply communities around the world with medical countermeasures that protect against serious health threats like smallpox and anthrax,” said Joe Papa, president and CEO of Emergent. “We are pleased to engage and support global partners in fulfilling their preparedness needs. As part of our multi-year transformation plan, we will continue to focus on international expansion efforts and strengthening health preparedness at home and abroad.” Emergent specializes in developing, manufacturing, and supplying MCMs for nati
Show less
Read more
Impact Snapshot
Event Time:
EBS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EBS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EBS alerts
High impacting Emergent Biosolutions, Inc. news events
Weekly update
A roundup of the hottest topics
EBS
News
- Emergent Biosolutions (NYSE:EBS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.MarketBeat
- Emergent BioSolutions Receives U.S. FDA Approval for Drug Product Manufacturing of raxibacumab at its Winnipeg, Canada SiteGlobeNewswire
- Emergent Biosolutions (NYSE:EBS) had its "hold (c-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Emergent Biosolutions (NYSE:EBS) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=EBS&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street MarketBeat
- Emergent Biosolutions (NYSE:EBS) had its "hold (c-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
EBS
Earnings
- 10/29/25 - Beat
EBS
Analyst Actions
- 12/16/25 - HC Wainwright
EBS
Sec Filings
- 12/22/25 - Form 144
- 12/16/25 - Form 4
- 12/12/25 - Form 8-K
- EBS's page on the SEC website